No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
PRTA250117C5000
- 0.00
- 0.000.00%
15min DelayTrading Dec 24 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-67.43%PremiumJan 17, 2025Expiry Date10.35Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.54Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $48
Leerink Partners Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $40
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Prothena (PRTA) and CVS Health (CVS)
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Chardan Capital Initiates Coverage On Prothena Corp With Buy Rating, Announces Price Target of $40
Prothena Stock Soars Despite Study Miss